Rallybio (RLYB) Stock Statistics & Valuation Metrics

Rallybio has a market cap or net worth of $27.71M. The enterprise value is -$5.48M.

Rallybio has 42,243,774 shares outstanding. The number of shares has decreased by -2.65% in one year.

Rallybio’s return on equity (ROE) is -0.94 and return on invested capital (ROIC) is -97.54%.

The current PE Ratio of Rallybio is ―. Rallybio’s PEG ratio is 0.03.

In the last 12 months, Rallybio had revenue of 636.00K and earned -57.77M in profits. Earnings per share was -1.33.

In the last 12 months, operating cash flow was -35.00M and capital expenditures 0.00, giving a free cash flow of -35.00M billion.

Rallybio pays an annual dividend of ―, resulting in a dividend yield of ―

Rallybio upcoming earnings date is Mar 17, 2026, Before Open (Confirmed).

Rallybio as a current ratio of 10.87, with Debt / Equity ratio of 0.31%

In the past 12 months, Rallybio has paid 0.00 in taxes.

Rallybio EV to EBITDA ratio is -0.46, with an EV/FCF ratio of -0.57.

Rallybio has $59.32M in cash and marketable securities with $198.00K in debt, giving a net cash position of $59.12M billion.

Gross margin is 95.55%, with operating margin of -9511.95%, and net profit margin of -9084.12%.

The average price target for Rallybio is $1.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy